David Shook Sells 1,977 Shares of Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider David Shook sold 1,977 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $12.64, for a total value of $24,989.28. Following the transaction, the insider directly owned 20,923 shares in the company, valued at $264,466.72. This represents a 8.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyell Immunopharma Stock Up 3.8%

LYEL stock traded up $0.50 on Thursday, reaching $13.72. 142,506 shares of the company’s stock were exchanged, compared to its average volume of 97,895. The stock has a fifty day moving average of $19.45 and a 200-day moving average of $23.36. The firm has a market cap of $320.09 million, a PE ratio of -0.99 and a beta of -0.09. Lyell Immunopharma, Inc. has a twelve month low of $8.46 and a twelve month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting analysts’ consensus estimates of ($1.10). The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. On average, equities research analysts predict that Lyell Immunopharma, Inc. will post -7.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of large investors have recently modified their holdings of LYEL. AQR Capital Management LLC grew its stake in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma in the second quarter valued at about $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma in the second quarter valued at about $159,000. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $210,000. Finally, Walleye Capital LLC acquired a new stake in shares of Lyell Immunopharma in the second quarter valued at about $258,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LYEL shares. Needham & Company LLC reissued a “buy” rating and issued a $44.00 target price on shares of Lyell Immunopharma in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Robert W. Baird set a $49.00 price target on Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Finally, Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.